For the majority of patients at high-risk for biochemical recurrence of prostate cancer (PCa), new prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) research reaffirms a lack of sustained efficacy for monotherapy treatment with local radiation therapy or radical prostatectomy.
For the retrospective study, recently published in BJUI Compass, researchers reviewed PSMA PET/CT data for 145 patients who underwent local radiation therapy (RT) (42 patients), radical prostatectomy (RP) (77 patients) or both (26 patients) for PCa. All patients in the cohort were deemed to be at high-risk for biochemical recurrence (PSA > 2 ng/ml above nadir after RT or > 1 ng/ml after RP), according to the study.
The study authors found that 77 percent of the cohort (113 patients) had one or more…